Regulation of hepatic cholesteryl ester transfer protein expression and reverse cholesterol transport by inhibition of DNA topoisomerase II

Journal of Biological Chemistry

Volumn 290, Issue 23, 2015, Pages 14418-14429

  Liu, Mengyang ^a   Chen, Yuanli ^a   Zhang, Ling ^a   Wang, Qixue ^a   Ma, Xingzhe ^a   Li, Xiaoju ^a   Xiang, Rong ^a   Zhu, Yan ^b   Qin, Shucun ^c   Yu, Yang ^c   Jiang, Xian Cheng ^d   Duan, Yajun ^a   Han, Jihong ^a  

^a NANKAI UNIVERSITY   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c TAISHAN MEDICAL UNIVERSITY   (China)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; ESTERIFICATION; ESTERS; LIPOPROTEINS; METABOLISM; NUCLEIC ACIDS; PHYSIOLOGY; PROTEINS;

CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CHOLESTERYL ESTER TRANSFER PROTEINS; CHOLESTERYL ESTERS; HIGH DENSITY LIPOPROTEIN; NUCLEAR TRANSLOCATIONS; RECEPTOR-INTERACTING PROTEINS; TRIGLYCERIDE-RICH LIPOPROTEINS;

CHOLESTEROL;

ABC TRANSPORTER A1; CHOLESTEROL ESTER TRANSFER PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PROTEIN P21; RECEPTOR INTERACTING PROTEIN 140; RETINOID X RECEPTOR; SMALL INTERFERING RNA; TENIPOSIDE; TRANSCRIPTION FACTOR E2F1; TRIACYLGLYCEROL; CHOLESTEROL; GYRASE INHIBITOR; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPID ANALYSIS; LIVER CELL; METABOLIC REGULATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVERSE CHOLESTEROL TRANSPORT; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER; MALE; METABOLISM; PROTEIN TRANSPORT; TRANSCRIPTION INITIATION;

MUS MUSCULUS; ORYCTOLAGUS CUNICULUS;

ANIMALS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORPHAN NUCLEAR RECEPTORS; PROTEIN TRANSPORT; TENIPOSIDE; TOPOISOMERASE II INHIBITORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84930681965     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.643015     Document Type: Article

References (41)

1. Rader, D. J., and de Goma, E. M. (2014) Future of cholesteryl ester transfer protein inhibitors. Annu. Rev. Med. 65, 385-403
2. Zhong, S., and Sharp., D. S., Grove, J.S., Bruce, C., Yano, K., Curb, J.D., and Tall, A. R. (1996) Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97, 2917-2923
3. Zhou, H., Li, Z., Silver, D. L., and Jiang, X. C. (2006) Cholesteryl ester transfer protein (CETP) expression enhances HDL cholesteryl ester liver delivery, which is independent of scavenger receptor BI, LDL receptor related protein and possibly LDL receptor. Biochim. Biophys. Acta 1761, 1482-1488
4. Luo, Y., and Tall, A. R. (2000) Sterol up-regulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 105, 513-520
5. Viennois, E., and Pommier., A. J., Mouzat, K., Oumeddour, A., El Hajjaji, F. Z., Dufour, J., Caira, F., Volle, D. H., Baron, S., and Lobaccaro, J. M. (2011) Targeting liver X receptors in human health: deadlock or promising trail? Expert. Opin. Ther. Targets 15, 219-232
6. Repa, J. J., and Turley., S. D., Lobaccaro, J. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., and Mangelsdorf, D. J. (2000) Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524-1529
7. Terasaka, N., Hiroshima, A., Koieyama, T., Ubukata, N., Morikawa, Y., Nakai, D., and Inaba, T. (2003) T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536, 6-11
8. Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R., Laffitte, B. A., Chen, M., Noh, G., Goodman, J., Hagger, G. N., Tran, J., Tippin, T. K., Wang, X., Lusis, A.J., Hsueh, W. A., Law, R. E., Collins, J. L., Willson, T. M., and Tontonoz, P. (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. U.S.A. 99, 7604-7609
9. Heisig, P. (2009) Type II topoisomerases: inhibitors, repair mechanisms, and mutations. Mutagenesis 24, 465-469
10. Chikamori, K., and Grozav., A. G., Kozuki, T., Grabowski, D., Ganapathi, R., and Ganapathi, M. K. (2010) DN Atopoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr. Cancer Drug Targets 10, 758-771
11. Rabinovich, G. A., and Toscano, M. A. (2009) Turning "sweet" on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9, 338-352
12. de la Llera-Moya, M., Rothblat, G. H, Glick, J. M., and England, J. M. (1992) Etoposide treatment suppresses atherosclerotic plaque development in cholesterol-fed rabbits. Arterioscler. Thromb. 12, 1363-1370
13. Tavares, E. R., and Freitas., F. R., Diament, J., and Maranhão, R. C. (2011) Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions. Int. J. Nanomedicine 6, 2297-2304
14. Zhang, L., Jiang, M., Shui, Y., Chen, Y., Wang, Q., Hu, W., Ma, X., Li, X., Liu, X., Cao, X., Liu, M., Duan, Y., and Han, J. (2013) DNA topoisomerase II inhibitors induce macrophage ABCA1 expression and cholesterol efflux-an LXR-dependent mechanism. Biochim. Biophys. Acta 1831, 1134-1145
15. Hayek, T., Masucci-Magoulas, L., Jiang, X., Walsh, A., Rubin, E., Breslow, J. L., and Tall, A. R. (1995) Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J. Clin. Invest. 96, 2071-2074
16. Cazita, P. M., and Berti., J. A., Aoki, C, Gidlund, M., and Harada., L. M., Nunes, V. S., Quintão, E. C, and Oliveira, H. C. (2003) Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J. Lipid Res. 44, 33-40
17. Casquero, A. C, Berti, J. A., Salerno, A. G., Bighetti, E. J., Cazita, P. M., Ketelhuth, D. F., Gidlund, M., and Oliveira, H. C. (2006) Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice. J. Lipid Res. 47, 1526-1534
18. Naik, S.U., Wang, X., Da Silva, J.S., Jaye, M., Macphee, C. H., Reilly, M. P., Billheimer, J. T., Rothblat, G. H., and Rader, D. J. (2006) Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113, 90-97
19. Duan, Y., Chen, Y., Hu, W., Li, X., Yang, X., Zhou, X., Yin, Z., Kong, D., Yao, Z., Hajjar, D. P., Liu, L., Liu, Q., and Han, J. (2012) Peroxisome proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J. Biol. Chem. 287, 23667-23677
20. Zhou, X., Yin, Z., Guo, X., Hajjar, D. P., and Han, J. (2010) Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J. Biol. Chem. 285, 6316-6326
21. Wang, Q., Ma, X., Chen, Y., Zhang, L., Jiang, M., Li, X., Xiang, R., Miao, R., Hajjar, D. P., Duan, Y., and Han, J. (2014) Identification of interferon-7 as a new molecular target of liver X receptor. Biochem. J. 459, 345-354
22. Jakobsson, T., Osman, W., Gustafsson, J. A., Zilliacus, J., and Wärnmark, A. (2007) Molecular basis for repression of liver X receptor-mediated gene transcription by receptor-interacting protein 140. Biochem. J. 405, 31-39
23. Docquier, A., Augereau, P., Lapierre, M., Harmand, P. O., Badia, E., Annicotte, J. S., Fajas, L., and Cavaillès, V. (2012) The RIP140 gene is a transcriptional target of E2F1. PloS ONE 7, e35839
24. Sherr, C. J., and Roberts, J. M. (1999) CDK inhibitors: positiver and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512
25. Connell-Crowley, L., Harper, J. W., and Goodrich, D. W. (1997) Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Biol. Cell 8, 287-301
26. Park, S.H., Lim, J. S., and Jang, K. L. (2011) All-trans retinoic acid induces cellular senescence via up-regulation of p16, p21, and p27. Cancer Lett. 310, 232-239
27. Shah, P. K. (2007) Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur. Heart J. 28, 5-12
28. Tanigawa, H, and Billheimer., J. T., Tohyama, J., Zhang, Y., Rothblat, G., and Rader, D. J. (2007) Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 116, 1267-1273
29. Ikewaki, K., and Rader., D. J., Sakamoto, T., Nishiwaki, M., Wakimoto, N., and Schaefer., J. R., Ishikawa, T., Fairwell, T., Zech, L. A., and Nakamura, H. (1993) Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J. Clin. Invest. 92, 1650-1658
30. Brousseau, M. E., and Diffenderfer., M. R., Millar, J. S., Nartsupha, C, and Asztalos., B. F., Welty, F. K., Wolfe, M. L., Rudling, M., Björkhem, I., Angelin, B., and Mancuso., J. P., Digenio, A. G., Rader, D. J., and Schaefer, E. J. (2005) Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25, 1057-1064
31. Villard, E. F., El Khoury, P., Duchene, E., Bonnefont-Rousselot, D., Clement, K., Bruckert, E., Bittar, R., Le Goff, W., and Guerin, M. (2012) Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women. Arterioscler. Thromb. Vasc. Biol. 32, 2341-2349
32. Rye, K. A., and Barter, P. J. (2004) Formation and metabolism of prebetamigrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 24, 421-428
33. Rye, K. A., and Hime., N. J., and Barter, P. J. (1997) Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. J. Biol. Chem. 272, 3953-3960
34. Favari, E., Lee, M., Calabresi, L., Franceschini, G., Zimetti, F., Bernini, F., and Kovanen, P. T. (2004) Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J. Biol. Chem. 279, 9930-9936
35. Gauthier, A., Lau, P., Zha, X., Milne, R., and McPherson, R. (2005) Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler. Thromb. Vasc. Biol. 25, 2177-2184
36. -/- mice. J. Lipid Res. 54, 2647-2657
37. Gautier, T., de Haan, W., Grober, J., Ye, D., and Bahr., M. J., Claudel, T., Nijstad, N., Van Berkel, T. J., Havekes, L. M., Manns, M. P., Willems, S. M., Hogendoorn, P. C, Lagrost, L., Kuipers, F., Van Eck, M., Rensen, P. C, and Tietge, U. J. (2013) Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. J. Lipid Res. 54, 2195-2205
38. Ratni, H., and Wright, M. B. (2010) Recent progress in liver X receptorselective modulators. Curr. Opin. DrugDiscov. Devel. 13, 403-413
39. Ishimaru, C, Yonezawa, Y., Kuriyama, I., Nishida, M., Yoshida, H., and Mizushina, Y. (2008) Inhibitory effects of cholesterol derivatives on DNA polymerase and topoisomerase activities, and human cancer cell growth. Lipids 43, 373-382
40. Kim, J. H., Chae, M., Kim, W. K., Kim, Y. J., Kang, H. S., Kim, H. S., and Yoon, S. (2011) Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br. J. Pharmacol. 162, 773-784
41. Blaschke, F., Leppanen, O., Takata, Y., Caglayan, E., Liu, J., Fishbein, M. C., Kappert, K., Nakayama, K. I., Collins, A. R., Fleck, E., Hsueh, W. A., Law, R. E., and Bruemmer, D. (2004) Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ. Res. 95, e110-e123